<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071679</url>
  </required_header>
  <id_info>
    <org_study_id>CLS001-CO-PR-015</org_study_id>
    <secondary_id>2016-004702-34</secondary_id>
    <nct_id>NCT03071679</nct_id>
  </id_info>
  <brief_title>Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Evaluator-blinded, Vehicle-controlled Study to Explore the Pharmacodynamic Effects of Omiganan and Omiganan in Combination With Imiquimod in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maruho Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maruho Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the&#xD;
      pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2017</start_date>
  <completion_date type="Actual">March 7, 2017</completion_date>
  <primary_completion_date type="Actual">March 7, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Evaluation</measure>
    <time_frame>6 Days</time_frame>
    <description>Erythema grading scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Biomarkers)</measure>
    <time_frame>Within 2 Weeks</time_frame>
    <description>Local biomarker sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Histology)</measure>
    <time_frame>Within 2 Weeks</time_frame>
    <description>Histological parameters assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Immunohistochemistry)</measure>
    <time_frame>Within 2 Weeks</time_frame>
    <description>Identification of lymphocytes and lineage cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (TAP)</measure>
    <time_frame>Within 6 Days</time_frame>
    <description>Qualitatively and Quantitatively analyze biomarkers captured by Trans Epidermal Patch (TAP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pharmacodynamic (LSCI)</measure>
    <time_frame>Within 6 Days</time_frame>
    <description>Assess cutaneous microcirculation using laster speckle imager</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Colorimetry)</measure>
    <time_frame>Within 6 Days</time_frame>
    <description>Colorimetric assessment by erythema grading scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Photography)</measure>
    <time_frame>Within 2 Weeks</time_frame>
    <description>Photographs of treatment sites will be taken</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (Thermography)</measure>
    <time_frame>Within 2 Weeks</time_frame>
    <description>Skin temperature measurements will be taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local tolerability</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Visual Analogue Scale (NRS) pruritus and pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (AE)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Adverse Events will be collected throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Vital Signs)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Vital Signs will be collected throughout the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (Laboratory Safety Testing)</measure>
    <time_frame>2 Weeks</time_frame>
    <description>Lab samples collected in various timepoints within the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety (ECG)</measure>
    <time_frame>Within 3 Weeks</time_frame>
    <description>ECGs will be collected before beginning and end of study</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Omiganan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omiganan 1% and Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Omiganan 2.5% and Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan</intervention_name>
    <description>Omignan 1%, 2.5%</description>
    <arm_group_label>Omiganan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod</intervention_name>
    <description>Imiquimod 15mg</description>
    <arm_group_label>Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan 1% and Imiquimod</intervention_name>
    <description>Omiganan 1% and Imiquimod</description>
    <arm_group_label>Omiganan 1% and Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omiganan 2.5% and Imiquimod</intervention_name>
    <description>Omiganan 2.5% and Imiquimod</description>
    <arm_group_label>Omiganan 2.5% and Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vehicle</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects, 18 to 45 years of age, inclusive. Healthy status is&#xD;
             defined by absence of evidence of any active or chronic disease following a detailed&#xD;
             medical and surgical history, a complete physical examination including vital signs,&#xD;
             12-lead ECG, haematology, blood chemistry, blood serology and urinalysis.&#xD;
&#xD;
          -  Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight of&#xD;
             50 kg.&#xD;
&#xD;
          -  Fitzpatrick skin type I-III (Caucasian)&#xD;
&#xD;
          -  Subjects and their partners of childbearing potential must use effective&#xD;
             contraception, for the duration of the study and for 3 months after the last dose.&#xD;
&#xD;
          -  Able and willing to give written informed consent and to comply with the study&#xD;
             restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease associated with immune system impairment, including auto-immune diseases,&#xD;
             HIV and transplantation patients&#xD;
&#xD;
          -  Family history of psoriasis&#xD;
&#xD;
          -  History of pathological scar formation (keloid, hypertrophic scar)&#xD;
&#xD;
          -  Have any current and / or recurrent pathologically, clinical significant skin&#xD;
             condition.&#xD;
&#xD;
          -  Previous use of imiquimod/ resiquimod/ gardiquimod&#xD;
&#xD;
          -  Known hypersensitivity to the (non)investigational drug, drugs of the same class, or&#xD;
             any of their excipients.&#xD;
&#xD;
          -  Hypersensitivity for dermatological marker at screening&#xD;
&#xD;
          -  Requirement of immunosuppressive or immunomodulatory medication within 30 days prior&#xD;
             to enrollment or planned to use during the course of the study.&#xD;
&#xD;
          -  Use of topical medication (prescription or over-the-counter [OTC]) within 30 days of&#xD;
             study drug administration, or less than 5 half-lives (whichever is longer) in local&#xD;
             treatment area&#xD;
&#xD;
          -  Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of&#xD;
             enrollment.&#xD;
&#xD;
          -  Participation in an investigational drug or device study within 3 months prior to&#xD;
             screening or more than 4 times a year.&#xD;
&#xD;
          -  Loss or donation of blood over 500 mL within three months (males) or four months&#xD;
             (females) prior to screening&#xD;
&#xD;
          -  Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. (Koos) Burggraaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LUMC/Centre for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antimicrobial Cationic Peptides</mesh_term>
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

